47 completed, 8 terminated, 1 withdrawn. 19 Phase 1, 18 Phase 2, 17 Phase 3, 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 16, Terminated 3 |
| Phase 2 | 18 | Completed 14, Terminated 3, Withdrawn 1 |
| Phase 3 | 17 | Completed 15, Terminated 2 |
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow Acorda Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) CVT-301, Sinemet - Parkinson's Disease | Phase 1 | Completed | Acorda Therapeutics | 23 | 2019-03-05 | 2019-08-02 |
| A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users Tozadenant, Placebo oral tablet, d-amphetamine - Abuse Potential | Phase 1 | Terminated | Biotie Therapies Inc. | 26 | 2017-09-18 | 2018-08-13 |
| Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant Tozadenant - Hepatic Impairment | Phase 1 | Terminated | Biotie Therapies Inc. | 20 | 2017-06-30 | 2018-01-04 |
| Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease. Tozadenant - Idiopathic Parkinson Disease | Phase 3 | Terminated | Biotie Therapies Inc. | 66 | 2017-04-10 | 2019-05-03 |
| A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder CVT-427 (zolmitriptan inhalation powder) - Migraine | Phase 1 | Completed | Acorda Therapeutics | 60 | 2016-09-01 | 2018-02-14 |
| A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet® - Parkinson Disease | Phase 1 | Completed | Acorda Therapeutics | 24 | 2016-06-01 | 2016-10-26 |
| A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder) CVT-301, LIP, Placebo - Parkinson's Disease | Phase 1 | Completed | Acorda Therapeutics | 36 | 2016-06-01 | 2017-01-30 |
| A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers diazepam nasal spray - Healthy | Phase 1 | Completed | Acorda Therapeutics | 15 | 2016-01-01 | 2016-06-13 |
| A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma CVT-301 (levodopa inhalation powder), Carbidopa, Placebo - Asthma | Phase 1 | Completed | Acorda Therapeutics | 25 | 2015-12-01 | 2016-06-13 |
| A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults CVT-301, Carbidopa - Smoking | Phase 1 | Completed | Acorda Therapeutics | 60 | 2015-12-01 | 2016-07-14 |
| Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults zolmitriptan, CVT-427 (zolmitriptan inhalation powder), - Migraine | Phase 1 | Completed | Acorda Therapeutics | 21 | 2015-11-01 | 2016-06-06 |
| Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) diazepam nasal spray, diazepam rectal gel - Refractory Epilepsy | Phase 2 | Terminated | Acorda Therapeutics | 78 | 2015-06-01 | 2018-10-16 |
| An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse rHIgM22, Placebo - Multiple Sclerosis, Acute Relapsing | Phase 1 | Completed | Acorda Therapeutics | 27 | 2015-04-01 | 2018-08-22 |
| Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg - Post-ischemic Stroke | Phase 3 | Terminated | Acorda Therapeutics | 294 | 2015-04-01 | 2019-01-22 |
| Randomized Safety Study of CVT-301 Compared to an Observational Control Group CVT-301, Observational cohort - Idiopathic Parkinson's Disease | Phase 3 | Completed | Acorda Therapeutics | 408 | 2015-03-01 | 2019-05-28 |
| Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes CVT-301 - Idiopathic Parkinson's Disease | Phase 3 | Completed | Acorda Therapeutics | 325 | 2015-03-01 | 2019-08-14 |
| SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) SYN120, Placebo - Parkinson's Disease Dementia (PDD) | Phase 2 | Completed | Biotie Therapies Inc. | 82 | 2014-12-22 | 2019-04-19 |
| A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg - Post-Ischemic Stroke | Phase 3 | Completed | Acorda Therapeutics | 377 | 2014-12-01 | 2018-06-07 |
| An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray. diazepam nasal spray - Epilepsy | Phase 2 | Terminated | Acorda Therapeutics | 126 | 2014-12-01 | 2018-07-30 |
| Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes CVT-301 Low Dose, CVT-301 High Dose, Placebo - Idiopathic Parkinson's Disease | Phase 3 | Completed | Acorda Therapeutics | 351 | 2014-11-01 | 2019-05-28 |
Showing 20 of 56. Sign in to see all of them.
Multiple Sclerosis (15) · Parkinson Disease (10) · Demyelinating Diseases (4) · Muscle Spasticity (4) · Spinal Cord Injuries (4) · Epilepsy (3) · Asthma (2) · Heart Failure (2) · Ischemic Stroke (2) · Migraine Disorders (2) · Seizures (2) · Stress Disorders, Post-Traumatic (2) · Cerebral Palsy (1) · Drug Resistant Epilepsy (1) · Dyskinesias (1)
4-Aminopyridine (21) · Sugars (4) · Carbidopa (3) · Diazepam (3) · carbidopa, levodopa drug combination (3) · tozadenant (3) · nepicastat (2) · tizanidine (2) · Dextroamphetamine (1) · Dopamine beta-Hydroxylase (1) · Levodopa (1) · Midazolam (1) · Moxifloxacin (1) · Nasal Sprays (1) · Neuregulins (1)
United States (50) · Canada (15) · United Kingdom (4) · Czechia (3) · Poland (3) · Serbia (3) · Spain (3) · Israel (2) · Australia (1) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1)
Charles Oh, MD (6) · Andrew Eisen, MD (3) · Bonnie Faust (3) · Andrew Blight, PhD (2) · Enrique Carrazana, MD (2) · Gabriel Pardo, MD (2) · Harald Murck, MD, PhD (2) · Holly Roberts, MD (2) · Mathews Adera, MD (2) · Aaron Boster, MD (1) · Adam DiDio, MD (1) · Alan Schulman, MD (1) · Albert Lo, M.D, Ph.D. (1) · Andrew Blight (1)
PMID 19249634, PMID 20976768, PMID 23652269, PMID 25560174, PMID 26565077, PMID 28131322, PMID 30663606, PMID 32482490, PMID 32651338, PMID 33866196, PMID 35496758, PMID 37532622